Introduction {#Sec1}
============

In 2012, 1.1 million men were diagnosed with prostate cancer (PCa) worldwide, accounting for 15% of all cancer diagnoses in men. Thus, PCa is the second most common cancer in men and the fifth leading cause for cancer in men. With an estimated 307,000 deaths, PCa represents 6.6% of total male cancer mortality \[[@CR1]\]. In Austria, from 2012 to 2014, the 1- and 3-year survival rates were 95.3 and 92.7%, respectively, the 5-year survival rate was 92.1% from 2007 to 2011, and the 10-year survival rate was 91.2% from 2002 to 2006 \[[@CR2]\], indicating excellent survival rates of prostate cancer patients (PCaPs). However, PCa and its treatment are related with considerable side effects, including muscular atrophy, weight changes, pain, and an overall decrease in health-related quality of life (HRQol) \[[@CR3]\]. Side effects during prostate cancer treatment can cause serious health problems as well as a substantial limitation of HRQoL in patients suffering from the disease \[[@CR4]\]. Depressive symptoms, impaired cognitive performance, sexual dysfunction, loss of libido, penile shortening, and gynecomastia are meaningful side effects that usually affect the mental state and HRQoL of PCaPs \[[@CR4]--[@CR8]\]. These factors for mental distress might play a role in the development of increased risk of suicide in PCaPs \[[@CR5], [@CR9]\]. PCaPs undergoing androgen deprivation therapy (ADT) can additionally suffer from the symptoms of hot flushes, decreased physical activity, and detrimental changes of their body composition, which potentially leads to a deteriorated cardiovascular risk profile \[[@CR7], [@CR10]--[@CR14]\]. Moreover, sex steroid deficiency induced by ADT leads to a decline in trabecular density and a decrease in bone mineral density (BMD), which correlates with fracture risk \[[@CR15]\]. Furthermore, ADT is associated with an increased rate of fracture and fracture associated mortality \[[@CR16], [@CR17]\]. In a previously published systematic review, a qualitative overview of the meaningful effects of RE in the rehabilitation of PCa was performed \[[@CR18]\]. However, the number of high-quality randomized controlled trials (RCTs) has increased substantially since then. Therefore, we decided to perform a quantitative analysis of the currently available data.

Treatment of prostate cancer includes surgery, radiation therapy, targeted therapy, and chemotherapy. Furthermore, ADT is part of the standard therapy for patients suffering from high-risk disease, defined as those cases with stage T3 and T4 tumors, a Gleason score of 8 to 10 and PSA levels higher than 20 ng/mL, as well as locally advanced prostate cancer \[[@CR3], [@CR19]\]. ADT seems to be a valuable adjuvant to radiation therapy for high-risk prostate cancer \[[@CR19]\]. Almost half of all PCaPs receive ADT at some point in their therapy \[[@CR20], [@CR21]\]. Long-term ADT is known to improve mortality \[[@CR22]--[@CR24]\], but comes at the cost of treatment-related morbidity \[[@CR25]\]. PCaPs receiving ADT are susceptible to loss of muscle strength and muscle mass, as well as increase of fat mass \[[@CR12]--[@CR14]\]. Further side effects of ADT are alterations in lipolysis profile \[[@CR26], [@CR27]\] and insulin metabolism \[[@CR14], [@CR27], [@CR28]\] as well as increased arterial stiffness \[[@CR27], [@CR28]\]. These changes are accompanied with an increased risk for developing cardiovascular disease \[[@CR27], [@CR29]--[@CR31]\], diabetes mellitus type II \[[@CR29]\], and osteoporosis \[[@CR13], [@CR32]\]. ADT is related to earlier onset of serious myocardial infarctions, especially in PCaPs older than 65 years of age \[[@CR33]\]. Therefore, lifestyle changing interventions like dietary adjustments and exercise were recommended to mitigate cardiovascular risk \[[@CR30]\]. The negative changes of body composition that are particularly associated with ADT and their visible effect like muscle loss, gynecomastia, and female pattern weight gain are perceived as emasculating and hence associated with psychosocial morbidity in PCaPs \[[@CR9]\]. Consequently, preservation of body composition alone is already considered a positive outcome in PCaPs. Resistance exercise (RE) has shown beneficial effects not just in the general public, but in specific patient populations such as patients suffering from metabolic syndrome, chronic obstructive pulmonary disease, and cancer \[[@CR34]--[@CR36]\]. As the loss of muscle mass and increase of visceral fat mass may be a key factor in the development of cardiovascular disease \[[@CR37]\], RE, causing initiation of muscle hypertrophy, might be the medical training therapy of choice to effectively combat adverse body composition changes. Aerobic exercise (AE) might be a potent exercise modality to decrease visceral fat mass and to counteract an increased cardiovascular risk profile. In PCa, however, AE does not target the basic physiology of the problem, which is loss of muscle mass. Moreover, RE may indirectly have a beneficial effect on visceral fat mass via an upregulation of adipose tissue lipolysis, as mediated through adiponectin \[[@CR38]\]. RE seems to be a safe, feasible, and effective rehabilitation tool for PCaPs undergoing ADT \[[@CR18]\]. To our knowledge, no meta-analysis has recently investigated the effectiveness of RE in PCaPs. We hypothesize that RE has significant beneficial effects on muscle strength, physical performance and function, body composition, HRQoL, and fatigue in PCaPs. The aim of this meta-analysis was to quantify these effects.

Methods {#Sec2}
=======

A systematic literature research for RE intervention trials with PCaPs published in English language between January 1966 and 31st of December 2016 was conducted by using the scientific medical databases PubMed, MEDLINE, EMBASE, SCOPUS, and Cochrane Library. Further, reference lists of relevant publications were searched for additional studies. The search strategy included the search terms "resistance exercise," "resistance training," "strength training," "prostate cancer," "androgen deprivation therapy" and "androgen suppression therapy," and their possible variations. One thousand three hundred and forty-seven articles were found and screened for eligibility by title and abstract. One thousand two hundred and eighty studies had to be excluded for not meeting inclusion criteria \[unsuitable type of study (review, study protocol, pilot studies, conference abstracts, etc.), insufficient representation of RE in the intervention branch, inapplicable type of cancer (non-PCa), multiple search results\] which left 67 for full text analysis. Of those, 32 articles finally met inclusion criteria of being relevant RE intervention trials with RE either as the sole exercise intervention or in combination with any other exercise modality in PCaPs \[[@CR39]--[@CR70]\]. Seventeen of those 32 studies were identified as independent studies \[[@CR39]--[@CR55]\], which published the primary results of a specific population sample for the first time. Those studies included 1199 patients of which 580 were allocated to a RE intervention group. Most of those studies included only PCaPs on current or previous ADT \[[@CR39]--[@CR47], [@CR49], [@CR51], [@CR53], [@CR55]\], some included both PCaPs on ADT and non-ADT \[[@CR50], [@CR52], [@CR54]\] and one excluded PCaPs with adjuvant or neoadjuvant therapy after radical prostatectomy \[[@CR48]\]. In the other 15 trials, additional outcomes or analyses of the former studies were published \[[@CR56]--[@CR70]\]. This distinction was particularly important to prevent multiple representations of data of the same sample in our meta-analysis. Additionally, the content of one erratum \[[@CR41]\] was taken into account. An overview over the selection process is presented in Fig. [1](#Fig1){ref-type="fig"}. The process of systematic literature review as well as selection of suitable articles was conducted independently by two experienced researchers following the PRISMA reporting guidelines for systematic reviews and meta-analyses. For each study, results regarding body composition, strength, functional and cardiovascular performance, as well as HRQoL and fatigue were reviewed and used for meta-analysis.Fig. 1Flowchart of patient allocation and dropouts

Statistical analysis {#Sec3}
--------------------

All outcome variables measured with the same assessment method in five or more of the original studies were subject to meta-analyses. Outcome variables reported in less than five studies were not considered for meta-analysis as the results are considered unreliable when a small number of heterogeneous studies are used \[[@CR71]\]. For all variables, the relevant effect measure was the difference in means between the respective baseline and post-intervention values. The standard deviation of the differences was reported in one study \[[@CR64]\], while standard deviations of baseline and post-intervention values were reported in all other studies. For these studies, the (conservative) assumption of a zero correlation between pre- and post-intervention values was made when calculating the standard error of the difference in means.

A weighted random effects meta-analysis model was fitted for each outcome variable using the DerSimonian-Laird approach. Confidence intervals for the summary effect measure and *p* values for according tests of no effect were calculated using Knapp and Hartung adjustments. To investigate the possibility of publication bias, funnel plots were inspected (Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"}, [6](#Fig6){ref-type="fig"}, [7](#Fig7){ref-type="fig"}, and [8](#Fig8){ref-type="fig"}). In the funnel plots, triangular areas are displayed that are expected to contain 95% of the observed values given there is no heterogeneity between studies. Under the realistic assumption of heterogeneity, a larger fraction of studies may be found outside these areas. Statistical analyses were performed using the library metafor \[[@CR72]\] in the statistical computing environment R 3.1.Fig. 2Funnel plot for reported mean differences in bench press/chest press measurements Fig. 3Funnel plot for reported mean differences in leg press measurements Fig. 4Funnel plot for reported mean differences in body fat percentage Fig. 5Funnel plot for reported mean differences in whole body fat mass Fig. 6Funnel plot for reported mean differences in whole body lean mass Fig. 7Funnel plot for reported mean differences in trunk fat Fig. 8Funnel plot for reported mean differences in 400-m walking time

Results {#Sec4}
=======

Descriptive characteristics of the included studies that were published since October 2014 are presented in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. Details of studies that were published previously are presented elsewhere \[[@CR18]\].Table 1Study characteristics and main outcomes of the independent studies published since October 2014, details of previous studies published in Hasenoehrl et al. \[[@CR18]\]StudySampleMean age ± SD (years)Patient details/cancer treatmentDuration of intervention (weeks)Exercise program detailsFrequency, duration, and intensityKey findings/commentsLivingston \[[@CR52]\]EI *n* = 54\
Cont (usual care) *n* = 93EI 66.9 ± 8.2\
Cont 64.7 ± 8.7Men who have completed active treatment for PCa within the previous 3 to 12 months\
RT: *n* = 42\
Surgery: *n* = 66\
RT + surgery: *n* = 39\
Currently on ADT: *n* = 3112Published in Gaskin et al. (2016):\
AE 20--30 min at 40--70% HFmax\
RE: 2 sets of 4--6 upper and lower body REs (unisonous exercises: 90° leg press, seated chest press, seated row)Training 3×/week (2×/week supervised at the gym, 50 min each; 1×/week home-based)Primary outcome: self-reported physical activity (Godin-Sheperd Leisure Time Exercise Questionnaire):\
↑ Vigorous-intensity activity (EI)\
↑ MVPA ≥150 min/week % (EI)\
Secondary outcomes:\
↔ PA (accelerometer)\
↔ QoL (EORTC-30)\
↓ Total anxiety (MAX-PC)\*\
↓ PSA anxiety (MAX-PC)\*\
↓ Fear of recurrence anxiety (MAX-PC)\*\
(↑) Cognitive function (EORTC-30)\
(↓) Depression symptoms (CES-D)\
\*Sig. effect found in Cont, no changes in EI!Nilsen \[[@CR53]\]EI *n* = 28\
Cont = 30 (usual care)EI 66 ± 6.6\
Cont 66 ± 5PCaPs with intermediate or high-risk\
profile referred to high-dose RT and (neo)adjuvant ADT (9--36 months)16RE only, progressive, heavy sessions supervised\
Smith machine half squat, leg press, Smith machine standing calf raises, knee flexion, knee extension, chest press, seated row, seated shoulder press, biceps curlsTraining 3×/week\
Weeks 1 and 2: familiarization 2× 10 reps at 40--50% 1RM\
Weeks 3--16:\
Mondays (heavy session): 1--3× 10RM\
Wednesdays (submaximal session):\
2--3× 10 reps at 80--90% of 10RM\
Fridays (heavy session): 2--3× 6RMBody composition:\
↔ LBM total and trunk\
↑ LBM lower extremities, upper extremities appendicular skeletal muscle (EI \> Cont)\
↔ Total and trunk fat mass, fat percentage\
↔ Body mass\
↔ BMI\
↔ Total and regional BMD\
Performance parameters:\
↑ Strength (1RM): leg press, chest press, shoulder press (EI \> Cont)\
↑ Sit to stand (EI \> Cont)\
↑ Stair climbing test (EI \> Cont)\
(↑) Shuttle walk (EI \> Cont)\
↔ Health-related QoL (EORTC-30)Winters-Stone \[[@CR54]\]64 couples (PCS + spouses)\
EI *n* = 32 couples\
Cont *n* = 32 couples (usual care)EI:\
PCS 70.6 ± 6.3\
Cont:\
PCS 72.9 ± 8.0PCS that received treatment for PCa, not currently undergoing chemo or RT\
RT: *n* = 28\
Surgery: *n* = 43\
Chemo: *n* = 2\
Currently on ADT: *n* = 1126Progressive partnered strength training, supervised\
Group exercise\
Lower body: chair rises, 90° squats, multi-directional lunges\
Upper body: rows, bench press, push-ups, triceps extension, shoulder raise2×/week, 1 h/session\
8--10 exercises/session\
5 min aerobic warm-up\
Lower body: 4--15% of bodyweight with weighted vest\
Upper body: 15-8RM\
5--10 min stretching cool-downOnly the results of the PCaPs are displayed:\
↔ Body composition (DXA): LBM, Fat mass, Trunk fat mass\
Maximal muscle strength (1RM):\
• ↑ Upper body muscle strength (bench press) EI \> Cont\
• ↔ Lower body muscle strength (single leg press)\
↔ Physical function (PPB)\
↔ Physical and mental health summary scales, physical function and fatigue subscales (SF-36)\
↑ Physical activity (CHAMPS) EI \> Cont\
No dropouts within EI!\
Mean adherence in PCS in EI 77%Hojan \[[@CR55]\]54 high-risk PCa\
EI *n* = 27\
Cont *n* = 27 (usual group)Overall 68.5 ± 6.1\
EI 67.4 ± 8.3\
Cont 69.9 ± 7.2High-risk PCa, undergoing RT and scheduled for ADT planned to continue for 36 months\
RT dose of 76 Gy in 38 fractions8Moderate-intensity physical exercise, supervised\
Alone and in groups\
AE: brisk walking, running, cycling\
RE: biceps curls, triceps extension, leg extension, leg curl, abdominal crunch5×/week, 50--55 min/session:\
5 min warm-up\
30 min AE\
15 min RE: 2× 8 reps at 70--75% of est1RM\
5 min cool-down\
MaxHR was set at 65--70% of estHFmax\
Cont: ADLsFunctional capacity: ↑ 6MWT; ↔ METs, dsypnoea (Borg Scale)\
Blood parameters: ↔ Hb, PSA, white blood cells, red blood cells, platelets, lymphocytes, IL-1β, IL-6, TNF-α\
Qol (EORTC QLQ-C30): ↑ Physical, emotional, and cognitive functioning\
↓ Fatigue\
QoL (QLQ-PR23): ↓ Incontinence aid\
Fatigue (FACT-G and -F): ↑ General score, fatigue score, physical/emotional/functional well-being,\
Sig. correlations in EI:\
• Between IL-6 and total QoL after RT (direct)\
• Between TNF-α and cognitive at baseline (direct)\
Sig. correlations in Cont:\
• Between IL-1β and fatigue after RT (inverse)\
• Between IL-6 and cognitive at baseline (direct)*AE* aerobic exercise, *RE* resistance exercise, *PCa* prostate cancer, *PCaP* prostate cancer patient, *QoL* quality of life, *PCS* prostate cancer survivor, *ADT* androgen deprivation therapy, *BMD* bone mineral density, *EI* exercise intervention, *Cont* control, *estHFmax* estimated maximum heart rate, *PA* physical activity, *1RM* one repetition maximum, *MVPA* moderate-vigorous physical activity, *PSA* prostate-specific antigen, *LBM* lean body mass, *RT* radiotherapy, *est1RM* estimated one repetition maximum, *ADLs* activities of daily living, *6MWT* 6-min walk test, *METs* metabolic equivalents, *Hb* hemoglobin, *PPB* physical performance battery, ↑ sig. increase, ↓ sig. decrease, ↔ no sig. change/difference, (↑) tendency to increase, (↓) tendency to decrease Table 2Results of the additional articles published since October 2014, details of previous studies published in Hasenoehrl et al. \[[@CR18]\]Additional articleExpansionResultsGaskin \[[@CR64]\]\
Additional article of Livingston \[[@CR52]\]Additional results\
Fitness outcomes• ↑ Aerobic fitness (6-min walk test)\
• ↑ Upper body maximal strength (1RM, 90° leg press)\
• ↑ Lower body maximal strength (1RM, seated chest press)\
• ↑ Lower body muscular endurance (sit to stand test)\
• ↑ Balance (functional reach test)\
• ↔ BMI\
• ↔ Girth measurements (chest, waist, hips, upper arm, mid-thigh)\
• ↔ Resting heart rate\
• ↔ Blood pressureNilsen \[[@CR65]\]\
Additional article of Nilsen \[[@CR53]\]Additional results\
Muscle cellular outcomes (biopsies)\
EI: *n* = 12\
Cont: *n* = 11Muscle fiber CSA\
• (↑) Within group difference (EI)\
• ↔ Within group difference (Cont)\
• ↑ Between group difference (EI \> Cont) (larger effect in type II fibers)\
Number of myonuclei\
• ↑ Within group difference (EI)\
• ↔ Within group difference (Cont)\
• (↑) Between group difference (EI \> Cont)\
Myonuclear domain\
• ↔ EI and Cont within group difference\
• ↔ EI vs. Cont between group difference\
Myonuclei per muscle fiber\
• ↑ EI type I fibers\
Muscle fiber CSA/myonuclei\
• ↓ EI type I fibers\
Number of satellite cells\
• ↔ EI and Cont, EI vs. Cont\
↔ Androgen receptor and myostatin\
Muscle strength (knee extensor 1RM)\
• ↑ Within group difference (EI)\
• ↔ Within group difference (Cont)\
• ↑ Between group difference (EI \> Cont)Nilsen \[[@CR66]\]\
Additional article of Nilsen \[[@CR53]\]Additional results\
Muscle cellular stress\
EI: *n* = 16\
Cont: *n* = 15Mitochondrial proteins, between group effects:\
• ↔ Citrate synthase\
• ↔ Cytochrome c oxidase subunit IV (COXIV)\
• ↔ HSP60\
Mitochondrial proteins, within group effects:\
• (↓) Citrate synthase in Cont\
Indicators of muscle cellular stress, between group effects:\
• ↔ HSP70\
• ↔ Alpha-B crystallin\
• ↔ HSP27\
• ↔ Free ubiquitin\
• ↔ Total ubiquinated proteins\
Indicators of muscle cellular stress, within group effects:\
• ↓ HSP70 in EIBuffart \[[@CR67]\]\
Additional article of Galvao \[[@CR45]\]Moderator and mediator analysisModerators:\
• Marital status moderated the effect of EI on global QoL in favor of married patients (no difference in attendance).\
• Time since diagnosis moderated the effect of EI on global QoL and physical, emotional, cognitive, and social function with a smaller effect in patients who started exercising later after diagnosis compared with those who started sooner (no association with attendance).\
• Significant moderation effect of presence of comorbidity on cognitive function with a larger effect in patients with comorbidities.\
• Borderline moderation effect of biphosphonate use on physical, role, and emotional function in favor of patients who previously used biphosphonates (no difference in attendance).\
Mediators and associations:\
• Chair rise time significantly mediated effect of EI on global QoL and physical and social function.\
• Chair rise test improvements associated with improvements in global QoL and physical and social function.\
• Self-reported PA increases associated with improvements in global QoL.\
• Fatigue reductions associated with improvements in global QoL and physical, role, emotional, and social function.\
• Distress reductions associated with improvements in global QoL and physical and role function.\
• Falls self-efficacy improvements associated with improvements in global QoL and physical, role, and social function.\
• No significant mediating effects on health-related QoL outcomes for aerobic fitness, physical activity, fatigue, distress, or falls self-efficacy.Gilbert \[[@CR68]\]\
Additional article of Bourke \[[@CR40]\]Additional results\
Endothelial functionResults from a subset of 50 subjects from the original trial (25 EI + 25 Cont):\
Vascular assessments/endothelial function:\
• ↑ FMD at 12 weeks\
• (↓) Diastolic blood pressure\
• ↔ Systolic blood pressure\
Body composition (BiA):\
• ↑ Skeletal muscle mass at 12 weeks\
• ↔ Lipid profile\
Blood markers:\
• ↑ SHBG\
• ↔ Total testosterone, free androgen index, PSA\
Exercise tolerance:\
• ↑ Treadmill walk time at 12 and 24 weeks\
Exercise and dietary behavior:\
• ↑ Exercise behavior (Godin LSI) at 12 weeks\
• ↔ Dietary behaviorLyons \[[@CR69]\]\
Additional article of Winters-Stone \[[@CR54]\]Additional results\
Levels of physical intimacyEngagement in affectionate and sexual behaviors\
• Engagement in affectionate behaviors: ↑ wives and ↔ husbands in the EI group compared to Cont\
• Engagement in sexual behaviors: ↔ husbands and wivesWinters-Stone \[[@CR70]\]\
Additional article of Winters-Stone \[[@CR51]\]Additional results\
Body composition, blood biomarkers\
Moderation and mediation analysisBody composition and blood biomarkers\
• ↓ Total fat\
• (↓) Percent body fat\
• (↓) Trunk fat\
• ↔ Lean mass\
• ↔ Insulin\
• ↔ IGF-1\
• ↔ SHBG\
• (↑) Physical activity energy expenditure\
Moderation and mediation analysis\
• Age moderates the insulin response to exercise (insulin reductions were smaller with increasing age)\
• Sig. indirect effect of loss of total fat mass and loss of trunk fat mass on group differences in insulin from baseline to 12 months*Cont* control group, *BMI* body mass index, *EI* exercise intervention, *QoL* quality of life, *PSA* prostate-specific antigen, *IGF-1* insulin-like growth factor 1, *1RM* one repetition maximum, *HSP* heat shock protein, *FMD* flow-mediated dilatation, *BiA* bioelectrical impedance analysis, *LSI* Leisure Score Index, *SHBG* sex hormone-binding globulin, ↑ sig. increase, ↓ sig. decrease, ↔ no sig. change/difference, (↑) tendency to increase, (↓) tendency to decrease

Risk of bias analysis {#Sec5}
---------------------

The funnel plot of lower body muscle strength (leg press) (Fig. [3](#Fig3){ref-type="fig"}) was suspicious, but the variable remained in the analysis due to reasons addressed in the discussion section. Funnel plots of the other outcome variables showed no sign of publication bias.

Muscle strength {#Sec6}
---------------

The results of bench press/chest press 1RM measurements were pooled from eight studies \[[@CR42]--[@CR45], [@CR53], [@CR54], [@CR63], [@CR64]\]. The difference in means for measurements was found to be significantly greater than zero, with an estimated increase of 5.24 kg (CI \[2.52, 7.97\]; *p* \< 0.001). The results are presented in Fig. [9](#Fig9){ref-type="fig"}. Eight studies examined effects of RE on lower body strength by assessing the 1RM leg press \[[@CR42]--[@CR44], [@CR46], [@CR53], [@CR54], [@CR63], [@CR64]\]. The pooled results of seven studies \[[@CR42]--[@CR44], [@CR53], [@CR54], [@CR63], [@CR64]\] showed that the difference in means for leg press was significantly greater than zero, with an estimated increase of 28.20 kg (CI \[10.51, 45.88\]; *p* = 0.008) (Fig. [10](#Fig10){ref-type="fig"}). In both strength measurements, the results of Hanson et al. (2013) had to be disregarded for meta-analysis because mean values were not presented \[[@CR46]\].Fig. 9Mean differences in bench press/chest press strength measurements in the original studies and summarized estimate from the random effects meta-analysis model. Positive values indicate increases in strength and therefore a beneficial effect of RE. Intervals are 95% confidence intervals Fig. 10Mean differences in leg press strength measurements in the original studies and summarized estimate from the random effects meta-analysis model. Positive values indicate increases in strength and therefore a beneficial effect of RE. Intervals are 95% confidence intervals

Body composition {#Sec7}
----------------

Body fat percentage was assessed in 11 studies \[[@CR41]--[@CR47], [@CR50], [@CR53], [@CR54], [@CR70]\], all but one assessed with dual x-ray absorptiometry (DXA) \[[@CR47]\]. The difference in means for body fat percentage was significantly smaller than zero, with an estimated decrease of 0.66% (CI \[−0.79, −0.53\]; *p* \< 0.001, Fig. [11](#Fig11){ref-type="fig"}).Fig. 11Mean differences in body fat percentage in the original studies and summarized estimate from the random effects meta-analysis model. Positive values indicate increases in strength and therefore a beneficial effect of RE. Intervals are 95% confidence intervals

Whole body fat mass was assessed in ten of the included studies \[[@CR41]--[@CR46], [@CR53], [@CR54], [@CR68], [@CR70]\]. The difference in means for whole body fat mass was not significantly different from zero but showed a tendency to decrease (CI \[−1.04, 0.06\] kg; *p* = 0.075, Fig. [12](#Fig12){ref-type="fig"}).Fig. 12Mean differences in whole body fat mass in the original studies and summarized estimate from the random effects meta-analysis model. Positive values indicate increases in strength and therefore a beneficial effect of RE. Intervals are 95% confidence intervals

The results of whole body lean mass was pooled from seven studies that all used DXA \[[@CR41], [@CR42], [@CR44]--[@CR46], [@CR53], [@CR54]\]. The difference in means for whole body lean mass was significantly greater than zero, with an estimated increase of 1 kg (CI \[0.15, 1.84\]; *p* = 0.028, Fig. [13](#Fig13){ref-type="fig"}).Fig. 13Mean differences in whole body lean mass in the original studies and summarized estimate from the random effects meta-analysis model. Positive values indicate increases in strength and therefore a beneficial effect of RE. Intervals are 95% confidence intervals

Trunk fat mass was assessed with DXA in seven studies \[[@CR41], [@CR42], [@CR44], [@CR45], [@CR53], [@CR54], [@CR70]\]. The difference in means for trunk fat mass was significantly smaller than zero, with an estimated decrease of 0.4 kg (CI \[−0.73, −0.08\]; *p* = 0.024, Fig. [14](#Fig14){ref-type="fig"}).Fig. 14Mean differences in trunk fat mass in the original studies and summarized estimate from the random effects meta-analysis model. Positive values indicate increases in strength and therefore a beneficial effect of RE. Intervals are 95% confidence intervals

Physical performance {#Sec8}
--------------------

As measurement of cardiovascular fitness, six studies performed a 400-m walk test \[[@CR41]--[@CR46]\]. As Hanson \[[@CR46]\] did not present mean values, the results of the remaining five studies \[[@CR41]--[@CR45]\] were pooled for the meta-analysis. The difference in means for the 400-m walk is significantly smaller than zero, with an estimated decrease of 18.10 s (CI \[−21.55, −14.65\]; *p* \< 0.001, Fig. [15](#Fig15){ref-type="fig"}).Fig. 15Mean differences in 400-m walking time in the original studies and summarized estimate from the random effects meta-analysis model. Positive values indicate increases in strength and therefore a beneficial effect of RE. Intervals are 95% confidence intervals

Functional performance, HRQoL, fatigue {#Sec9}
--------------------------------------

Functional performance was assessed in several studies with different outcome variables. Quoted in excerpts, the 6-m walk was assessed in five studies \[[@CR42]--[@CR44], [@CR46], [@CR73]\], repeated chair rise \[[@CR42]--[@CR45]\] and sit-to-stand test \[[@CR39], [@CR46], [@CR53], [@CR64]\] in four studies, and Timed Up and Go test in two studies \[[@CR41], [@CR46]\]. Sufficient data existed for the 400-m walk tests only, which were subject to meta-analysis.

HRQol was assessed in 12 studies, but the assessment methods were very heterogeneous; therefore, there was no sufficient data for meta-analysis \[[@CR39]--[@CR42], [@CR44]--[@CR47], [@CR49], [@CR50], [@CR53], [@CR54]\].

Fatigue was assessed in nine studies \[[@CR39]--[@CR42], [@CR46], [@CR47], [@CR49], [@CR50], [@CR53]\]. Five studies assessed fatigue with the FACT-F \[[@CR39], [@CR40], [@CR47], [@CR49], [@CR50]\], but only four presented sufficient data for the meta-analysis. Therefore, meta-analysis for fatigue was not feasible.

Discussion {#Sec10}
==========

The results of the present meta-analysis showed that there are several beneficial effects for PCaPs associated with RE. Both lower and upper body muscle strength and cardiovascular fitness as well as measures of body composition increased significantly.

Regarding body composition, the results of this meta-analysis showed a significant decrease of whole body fat percentage and trunk fat, as well as a significant increase of whole body lean mass in PCaPs who performed RE. This is of particular interest, since preserving body composition itself should be considered a positive outcome in RE for PCaPs.

Just like suffering from cancer and various other treatment modalities (e.g., radiation therapy and chemotherapy), ADT is associated with reduced functional performance, impaired dynamic balance, and decreases in strength. These factors affect risk of falls and successful performance of activities of daily living (ADL) \[[@CR32], [@CR74]\]. The preservation of physical performance levels as shown in this meta-analysis should be seen as a further positive clinical outcome of RE in PCaPs. In accordance to this finding, quantitative analysis of currently available data showed that physical performance parameters significantly increased with RE. Further, PCaPs significantly improved upper and lower body strength while performing RE which we argue could decrease fall risk and increase ADL performance. It has been noted that results of 400-m walk time tests---where participants walk laps in a marked corridor aiming to complete the full distance as quickly as possible---have to be treated with caution \[[@CR75]\]. Although the meta-analysis showed a significant decrease of 18.10 s, Kwon et al. (2009) described a minimally meaningful change of 20--30 s \[[@CR76]\]. Their study, however, analyzed sedentary, elderly patients, and it is possible that smaller changes might prove to be clinically relevant for larger PCaPs cohorts. Moreover, physical performance is an important factor for PCaPs to maintain HRQoL \[[@CR77]--[@CR80]\]. Therefore, an increase in physical performance seems to be directly related to the patients' ability to at least maintain if not to improve HRQoL. Unfortunately, as already described in the methods section, the available data regarding HRQoL was insufficient for meta-analysis because too many different assessment methods (FACT-P, QLQ-PR25, PORPUS, EORTC-C30, SF-36) were used within relevant studies. This heterogeneity among studies concerning assessment methods can be seen as a limitation of the present meta-analysis, and greater effort for international consensuses regarding HRQoL assessment is dearly needed to facilitate research in this field. Furthermore, although RE was performed in all studies included, heterogeneity in training methods still existed to a certain extent between interventions. Most of the studies that were included performed at moderate to high intensities in the range of the 15--6 repetition maximum (about 60--85% of 1RM) \[[@CR40]--[@CR45], [@CR47], [@CR49], [@CR53], [@CR54], [@CR63], [@CR64], [@CR70]\]. In two studies, light to moderate loads were used for exercise (bodyweight, 50--70% of 1RM) \[[@CR39], [@CR48]\]. The participants of the study by Hanson et al. performed RE at very high intensity (5RM) \[[@CR46]\]. Their results for body fat percentage and body fat mass did not differ substantially from the other studies that were included in this meta-analysis (Figs. [11](#Fig11){ref-type="fig"} and [12](#Fig12){ref-type="fig"}), but their results for whole body lean mass were the only ones reaching statistical significance (Fig. [13](#Fig13){ref-type="fig"}) \[[@CR30]\]. This could have affected the pooled results of the meta-analysis of effects of RE on whole body lean mass towards a positive outcome. Nevertheless, we decided to include these results because they seem to provide an indication that high-intensity RE might be superior to moderate- to high-intensity RE if muscle hypertrophy is seen as the primary goal of exercise in PCaPs. Another limitation of this meta-analysis is that due to the small number of high-quality RCTs, both studies conducting RE as the sole intervention and studies conducting RE in combination with other exercise interventions were included. Future meta-analyses, able to select more studies including higher numbers of patients receiving solely RE or RE in combination exercise, are recommended to evaluate potentially different outcomes in PCaPs. However, as a specific training stimulus can be attributed to a functional outcome, we do not perceive the incorporation of combined RE interventions in our analyses as a major problem. As previously reported, RE is primarily associated with an increase in strength and lean body mass, whereas AE is primarily associated with adaptations of the cardiovascular system. Therefore, the bench press outcome of a combined training intervention study should not be affected by the AE intervention (e.g., cycling) but the RE intervention only. For a more complex understanding of exercise interventions in PCaPs, future meta-analyses should aim to isolate the results of home-based exercise trials from those of trials with supervised training sessions, as AE in a home-based environment seems to be easier to perform than RE, which in contrast seems to be more difficult to perform without supervision \[[@CR47]\].

In order to check for publication bias, funnel plots were inspected (Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"}, [6](#Fig6){ref-type="fig"}, [7](#Fig7){ref-type="fig"}, and [8](#Fig8){ref-type="fig"}). On the one side, leg press performance was untypically low in the study by Winters-Stone et al. (2016) \[[@CR38]\]. On the other side, the respective results were untypically high and unsteady in the trial by Galvao et al. (2006) \[[@CR27]\] (Fig. [3](#Fig3){ref-type="fig"}). This difference might be due to different exercises and assessment methodologies used in these studies. In the study of Winters-Stone et al. (2016), RE for the lower body was performed with bodyweight and weighted vests \[[@CR38]\]. From the sensorimotor perspective, this kind of RE has its advantages over machine-based RE. However, it might be limited regarding the development of sheer leg strength, especially when the participants are elderly PCaPs receiving cancer treatment and when strength outcome is measured with a standard 1RM test on the leg press. Galvao et al. (2006) \[[@CR27]\], on the other hand, who reported very high outcomes, did not only assess 1RM but also measured muscle endurance. Their participants performed the maximal number of repetitions at 70% of their 1RM and, in contrast to the participants of the other studies, might therefore have had a learning effect when performing at complete exhaustion, which might be a decisive factor for 1RM performance \[[@CR81]\]. The seeming deviation of these studies might thus be rather due to study heterogeneity, which was accounted for in the meta-analysis, and not due to publication bias.

A prevalent shortcoming in all of the included studies was the lack of blinding of the participants. This notion can be explained by the nature of randomized controlled exercise intervention studies, where blinding is not feasible.

Conclusion {#Sec11}
==========

In the present meta-analysis, we were able to confirm that RE is a potent approach in counteracting increase of body fat as well as loss of muscle mass, muscle strength, and physical performance in patients suffering from prostate cancer. RE should be an important part in multidisciplinary and interdisciplinary cancer rehabilitation of this patient group as it seems to have notable potential to reduce not only treatment-related side effects but also detrimental psychosocial health issues \[[@CR9], [@CR18]\]. Many PCaPs are undergoing long-term ADT \[[@CR82]\], while substantial ADT side effects are already measurable after 3 months of treatment \[[@CR83]\]. Therefore, implementation of RE as an early countermeasure as well as within a long-term rehabilitation process of PCa is essential in optimal supportive care of PCaPs. Nevertheless, further and larger studies examining different protocols of RE and their effectiveness at different treatment and disease stages should be key components of future research in this field.
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